ArticleScientific reports2019
Toll-like Receptor-4 Activation Boosts the Immunosuppressive Properties of Tumor Cells-derived Exosomes.
Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 41 citations in OpenAlex.
- Review
- The gut-tumor connection: the role of microbiota in cancer progression and treatment strategies.Journal of advanced research · 2026Review
- Toll-Like Receptor-4 Signaling Pathway Influenced the Exosome Biogenesis and Angiogenesis in Human Triple-Negative Breast Cancer Cells.Advanced pharmaceutical bulletin · 2025Article
- In vivo mechanisms of resveratrol liposomes in targeting the TLR4/NLRP3 pathway in lung cancer.Scientific reports · 2025Article
- Role of the oral-gut microbiota axis in pancreatic cancer: a new perspective on tumor pathophysiology, diagnosis, and treatment.Molecular medicine (Cambridge, Mass.) · 2025Review
- Intratumoral microbiome: implications for immune modulation and innovative therapeutic strategies in cancer.Journal of biomedical science · 2025Review
- Emerging roles of intratumoral microbiota: a key to novel cancer therapies.Frontiers in oncology · 2025Review
- IntratumoralPathogens (Basel, Switzerland) · 2024Review
- Review
- Research progress on the impact of intratumoral microbiota on the immune microenvironment of malignant tumors and its role in immunotherapy.Frontiers in immunology · 2024Review
- Single-cell profiling of murine bladder cancer identifies sex-specific transcriptional signatures with prognostic relevance.iScience · 2023Article
- Awareness of intratumoral bacteria and their potential application in cancer treatment.Discover oncology · 2023Review
- Immunotherapeutic Implications of Toll-like Receptors Activation in Tumor Microenvironment.Pharmaceutics · 2022Review
- Lipid A Mimetics Based on Unnatural Disaccharide Scaffold as Potent TLR4 Agonists for Prospective Immunotherapeutics and Adjuvants.Chemistry (Weinheim an der Bergstrasse, Germany) · 2022Article
- TLR4 Expression in Ex-Lichenoid Lesions-Oral Squamous Cell Carcinomas and Its Surrounding Epithelium: The Role of Tumor Inflammatory Microenvironment.Biomolecules · 2022Article
- Exosomes: A potential tool for immunotherapy of ovarian cancer.Frontiers in immunology · 2022Review
- The effect of the intratumoral microbiome on tumor occurrence, progression, prognosis and treatment.Frontiers in immunology · 2022Review
- Pro-Inflammatory Microenvironment Modulates the Transfer of Mutated TP53 Mediated by Tumor Exosomes.International journal of molecular sciences · 2021Article
- Association between serum soluble Toll-like receptor 2 and 4 and the risk of breast cancer.Molecular and clinical oncology · 2021Article
- Exosomes in Immune Regulation.Non-coding RNA · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The biology of tumor-derived exosomes (TEX) is only partially understood and much remains to be studied in order to define the effect that the tumor microenvironment or the activation of tumor cells exerts on their composition and functions. Increased expression and activity of toll-like receptor 4 (TLR4) in chronic infectious and inflammatory conditions is related with cancer progression: its activation induces an inflammatory signaling that increases the tumorigenic potential of cancer cells promoting their immune evasion. We investigated the immune modulatory properties of TEX released upon cell TLR4 activation, and we found that, although differences were observed depending on the type of the tumor, the treatment influences TEX composition and boosts their immunosuppressive ability. Our results suggest that the activation of TLR4 supports tumor progression by stimulating the release of more effective immunosuppressive exosomes, which allow tumor cells to escape immune surveillance and probably even play a role in the metastatic process.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.